Catalent (CTLT) 10-Q 3 Nov 15 2015 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q1
Entity Registrant Name	Catalent, Inc.
Entity Central Index Key	1,596,783
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding (shares)		124,521,872

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net revenue	$ 423	$ 418.3
Cost of sales	301.5	293
Gross margin	121.5	125.3
Selling, general and administrative expenses	82.2	81.4
Impairment Charges And Gain Loss On Sale Of Assets	1.2	0
Restructuring and other	1	1.4
Operating earnings/(loss)	37.1	42.5
Interest expense, net	22.7	35.5
Nonoperating Income (Expense)	(0.6)	(41.3)
Earnings/(loss) from continuing operations before income taxes	13.8	(34.3)
Income tax expense/(benefit)	4.9	(14)
Earnings/(loss) from continuing operations	8.9	(20.3)
Net earnings/(loss) from discontinued operations, net of tax	0	0.4
Net earnings/(loss)	8.9	(19.9)
Less: Net earnings/(loss) attributable to noncontrolling interest, net of tax	(0.2)	(0.4)
Net earnings/(loss) attributable to Catalent	9.1	(19.5)
Earnings/(loss) from continuing operations less net earnings (loss) attributable to noncontrolling interest	$ 9.1	$ (19.9)
Income (Loss) from Continuing Operations, Per Basic Share	$ 0.07	$ (0.19)
Earnings Per Share, Basic	0.07	(0.18)
Income (Loss) from Continuing Operations, Per Diluted Share	0.07	(0.19)
Earnings Per Share, Diluted	$ 0.07	$ (0.18)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Other comprehensive income/(loss), net of tax
Net earnings/(loss)	$ 8.9	$ (19.9)
Foreign currency translation adjustments	(42.4)	(53.8)
Pension and Other Post-Retirement adjustments	0.5	0.4
Deferred compensation	(0.7)	(0.2)
Net current period other comprehensive income (loss)	(42.6)	(53.6)
Comprehensive income/(loss)	(33.7)	(73.5)
Comprehensive income/(loss) attributable to noncontrolling interest	(0.2)	(0.2)
Comprehensive income/(loss) attributable to Catalent	$ (33.5)	$ (73.3)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 151.4	$ 151.3
Trade receivables, net	308.2	372.4
Inventories	150.9	132.9
Prepaid expenses and other	80.7	80.9
Total current assets	691.2	737.5
Property, plant, and equipment, net	884.3	885.2
Other assets:
Goodwill	1,038.1	1,061.5	[1]
Other intangibles, net	348.1	368.7
Deferred income taxes	67.5	64.1
Other	27.2	28.4
Total assets	3,056.4	3,145.4
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND SHAREHOLDERS' EQUITY/(DEFICIT)
Current portion of long-term obligations and other short-term borrowings	24	23.8
Accounts payable	127.4	128.2
Other accrued liabilities	201.5	247
Total current liabilities	352.9	399
Long-term Debt and Capital Lease Obligations	1,859.9	1,864.1
Pension liability	141.8	143.7
Deferred income taxes	57.7	56.3
Other liabilities	41.1	$ 42.5
Commitment and contingencies (see Note 13)
Redeemable Noncontrolling Interest, Equity, Carrying Amount	5.8	$ 5.8
Common stock	1.2	1.2
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	1,970.4	1,973.7
Accumulated deficit	(1,157.8)	(1,166.9)
Accumulated other comprehensive income/(loss)	(216.6)	(174)
Total shareholders' equity/(deficit)	597.2	634
Noncontrolling interest	0	0
Total Catalent shareholders' equity/(deficit)	597.2	634
Total liabilities, redeemable noncontrolling interest and shareholders' equity/(deficit)	$ 3,056.4	$ 3,145.4
[1]	The opening balance is reflective of prior impairment charges.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Jun. 30, 2015
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	124,521,872	124,319,279
Common Stock, Shares, Outstanding	0	0
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholder's Equity - 3 months ended Sep. 30, 2015 - USD ($) $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Jun. 30, 2015	$ 634	$ 1.2	$ 1,973.7	$ (1,166.9)	$ (174)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity compensation	2.5		2.5
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	(5.6)		(5.6)
Noncontrolling Interest Ownership Changes	(0.2)		(0.2)
Net Income (Loss) Attributable to Parent	9.1			9.1
Net earnings/(loss)	9.1
Other comprehensive income/(loss), net of tax	(42.6)				(42.6)
Ending Balance at Sep. 30, 2015	$ 597.2	$ 1.2	$ 1,970.4	$ (1,157.8)	$ (216.6)

Consolidated Statement of Chan7

Consolidated Statement of Changes in Shareholder's Equity Consolidated Statement of Changes in Shareholders' Equity (Parenthetical)	3 Months Ended
	Sep. 30, 2015shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance - Common Stock Outstanding (shares)	0
Ending Balance - Common Stock Outstanding (shares)	0
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance - Common Stock Outstanding (shares)	124,319,300
Stock Issued During Period (shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (shares)	202,600
Ending Balance - Common Stock Outstanding (shares)	124,521,900

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015		Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings/(loss)	$ 8.9		$ (19.9)
Net earnings/(loss) from discontinued operations	0		0.4
Earnings/(loss) from continuing operations	8.9		(20.3)
Adjustments to reconcile (loss)/earnings from continued operations to net cash from operations:
Depreciation and amortization	35.5		35
Non-cash foreign currency transaction (gain)/loss, net	(0.1)		(11.2)
Amortization and write off of debt financing costs	1.1		12.4
Asset Impairment Charges And Gain Loss On Sale Of Assets	1.2		0
Business Combination, Bargain Purchase, Gain Recognized, Amount Net of Tax	0	[1]	7
Reclassification Of Call Premium Payment	0		9.8
Equity compensation	2.5		1.5
Increase (Decrease) in Deferred Income Taxes	1.2		7.7
Provision for bad debts and inventory	0.9		1.7
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables	59.7		62
Decrease/(increase) in inventories	(20.4)		(14.1)
Increase/(decrease) in accounts payable	1.6		(26.3)
Other accrued liabilities and operating items, net	(44.8)		(76)
Net cash provided by/(used in) operating activities from continuing operations	44.9		(40.2)
Net cash provided by/(used in) operating activities from discontinued operations	0		0.4
Net cash provided by/(used in) operating activities	44.9		(39.8)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets	(33.2)		(31.2)
Payment for acquisitions, net	0		(13.5)
Net cash provided by/(used in) investing activities from continuing operations	(33.2)		(44.7)
Net cash provided by/(used in) investing activities from discontinued operations	0		0
Net cash provided by/(used in) investing activities	(33.2)		(44.7)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in short-term borrowings	0		11.7
Proceeds from Bank Debt	0		0
Payments related to long-term obligations	(4.7)		(863.8)
Call Premium Paid For Redemption Of Debt	0		9.8
Equity contribution/(redemption)	0		948.8
Payments for Repurchase of Common Stock	(5.6)		0
Net cash (used in)/provided by financing activities from continuing operations	(10.3)		86.9
Net cash (used in)/provided by financing activities from discontinued operations	0		0
Net cash (used in)/provided by financing activities	(10.3)		86.9
Effect of foreign currency on cash	(1.3)		(13.6)
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS	0.1		(11.2)
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	151.3
CASH AND EQUIVALENTS AT END OF PERIOD	151.4		63.2
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid	20.8		44.3
Income taxes paid, net	$ 10		$ 9.9
[1]	During the three months ended September 30, 2014, the Company recorded a $7.0 million bargain purchase gain for an acquisition completed in July 2014.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Catalent, Inc. (“Catalent” or the “Company”) directly and wholly owns PTS Intermediate Holdings LLC (“Intermediate Holdings”). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. (“Operating Company”). The financial results of Catalent are solely comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. In July 2014, the Company’s board of directors and holders of the requisite number of outstanding shares of its capital stock approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 70 -for-1 stock split of its outstanding common stock (the “stock split”). The stock split became effective on July 17, 2014 upon the filing of the Company’s Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State. On the effective date of the stock split, (i) each outstanding share of common stock was increased to seventy shares of common stock, (ii) the number of shares of comm;on stock issuable under each outstanding option to purchase common stock was proportionately increased on a one-to-seventy basis, (iii) the exercise price of each outstanding option to purchase common stock was proportionately decreased on a one-to-seventy basis, and (iv) the number of shares underlying each restricted stock unit was proportionately increased on a one-to-seventy basis. All of the share and per share information referenced throughout the financial statements and notes to the consolidated financial statements have been retroactively adjusted to reflect this stock split. On July 31, 2014, the Company commenced an initial public offering of its common stock (the “IPO”). As part of its IPO, the Company sold a total of 48.9 million shares at a price of $20.50 per share, before underwriting discounts and commissions. Net of these discounts and commissions and other offering expenses, the Company obtained total proceeds from the IPO, including the underwriters’ over-allotment option, of $952.2 million , which it used to fully redeem the outstanding Senior Subordinated Notes, redeem the outstanding Senior Notes, repay portions of the Company’s unsecured term loan, and pay to Blackstone and certain other shareholders an advisory agreement termination fee of $29.8 million (recorded within other income/(expense), net on the Consolidated Statement of Operations), and for other corporate purposes. The Company’s common stock began trading on the New York Stock Exchange (the “NYSE”) under the symbol “CTLT” as of the IPO. Refer to Note 6 for further discussion regarding debt repayments. On March 9, 2015, an affiliate of The Blackstone Group, L.P. that owned shares in the Company (“Blackstone”), Genstar Capital and Aisling Capital (collectively the “selling stockholders”) completed a secondary offering of 27.3 million shares of the Company’s common stock, including 3.6 million shares sold pursuant to the over-allotment option granted to the underwriters at a price of $29.50 per share before underwriting discounts and commissions. On June 2, 2015, the selling stockholders completed an additional secondary offering of 16.1 million shares, including 2.1 million shares sold pursuant to the over-allotment option, at a price of $29.00 per share, before underwriting discounts and commissions. The Company did not sell any stock in either secondary offering and did not receive any proceeds of the sales. Blackstone’s ownership in the Company was reduced to 32.7% following the March offering and to 20.8% following the June offering, and as a result the Company ceased being a “controlled company” under applicable NYSE listing standards since March 9, 2015. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending June 30, 2016 . The consolidated balance sheet at June 30, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015 filed with the SEC. Noncontrolling interest is included within the equity section in the consolidated balance sheets. Redeemable noncontrolling interest has been classified as temporary equity and is therefore reported outside of permanent equity on the consolidated balance sheets at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net earnings/(loss) or its redemption value. The Company presents the amount of consolidated net earnings/(loss) that is attributable to Catalent and the noncontrolling interest in the consolidated statements of operations. Furthermore, the Company discloses the amount of comprehensive income that is attributable to Catalent and the noncontrolling interest in the consolidated statements of comprehensive income/(loss). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative financial instruments and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts. Foreign Currency Translation The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. The currency fluctuations related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the consolidated statements of operations in the other (income) expense, net line item. Foreign currency translation gains and losses generated from inter-company loans that are long-term in nature, but may be repayable in the foreseeable future, are also recorded within the other (income)/expense, net line item on the consolidated statements of operations. Revenue Recognition In accordance with Codification Standard ASC 605 Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. In cases where the Company has multiple contracts with the same customer, the Company evaluates those contracts to assess if the contracts are linked or are separate arrangements. Factors the Company considers include the timing of negotiation, interdependency with other contracts or elements and payment terms. The Company and its customers generally view each contract discussion as a separate arrangement. Manufacturing and packaging service revenue is recognized upon delivery of the product in accordance with the terms of the contract, which specify when transfer of title and risk of loss occurs. Some of the Company’s manufacturing contracts with its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the unfilled purchase obligation in accordance with the contract terms. Development service contracts generally take the form of a fee-for-service arrangement. After the Company has evidence of an arrangement, the price is determinable and there is a reasonable expectation regarding payment, the Company recognizes revenue at the point in time the service obligation is completed and accepted by the customer. Examples of output measures include a formulation report, analytical and stability testing, clinical batch production or packaging and the storage and distribution of a customer’s clinical trial material. Development service revenue is primarily driven by the Company’s Development and Clinical Services segment. Arrangements containing multiple elements, including service arrangements, are accounted for in accordance with the provisions of ASC 605-25 Revenue Recognition: Multiple-Element Arrangements . The Company determines the separate units of account in accordance with ASC 605-25. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price. Goodwill The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350 Goodwill, Intangible and Other Assets . Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company's annual goodwill impairment test was conducted as of April 1, 2015. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. In addition, the Company uses comparative market information and other factors to corroborate the discounted cash flow results. Property and Equipment and Other Definite Lived Intangible Assets Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following ranges of useful lives for its property and equipment categories: buildings and improvements - 5 to 50 years; machinery and equipment - 3 to 10 years; and furniture and fixtures - 3 to 7 years. Depreciation expense was $23.6 million for the three months ended September 30, 2015 and $23.7 million for the three months ended September 30, 2014 , respectively. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented. Intangible assets with finite lives, primarily including customer relationships and patents and trademarks continue to be amortized over their useful lives. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment . This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm's length transactions. Research and Development Costs The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general and administrative expenses. Such research and development costs included in selling, general and administrative expenses amounted to $1.6 million for the three months ended September 30, 2015 , and $2.8 million for the three months ended September 30, 2014 . Costs incurred in connection with research and development services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $11.8 million for the three months ended September 30, 2015 and $8.8 million for the three months ended September 30, 2014 , respectively. Earnings / (Loss) Per Share The Company reports net earnings/(loss) per share pursuant to ASC 260 Earnings per Share . Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net earnings or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net earnings or loss available to common stockholders by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share includes in-the-money stock options, restricted stock units, and restricted stock using the treasury stock method. During a loss period, the assumed exercise of in-the-money stock options has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share. Equity-Based Compensation The Company accounts for its equity-based compensation awards pursuant to ASC 718 Compensation-Stock Compensation . ASC 718 requires companies to recognize compensation expense using a fair value based method for costs related to share-based payments including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards that are expected to vest, and the expense is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate. The terms of the Company’s equity-based compensation plans permit shares that are issued upon an employee's exercise of an option to be withheld through a net settlement transaction as a means of meeting tax withholding requirements. Recent Financial Accounting Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2015-16, Simplifying the Accounting for Measurement Period Adjustments. The new standard eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment be recognized in the reporting period in which the adjustment is identified. The standard is effective for public entities for annual periods beginning after December 15, 2017. Early adoption is permitted. Catalent has determined the impact of this standard will be not be material on its consolidated results of operations and financial positio n. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . The new standard requires that debt issuance costs be presented in the balance sheet as a direct reduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The standard is effective for public entities for annual and interim periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. Catalent has determined the impact of this standard will be not be material on its consolidated results of operations and financial positio n. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers . The new standard will supersede nearly all existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the standard creates a five-step model that requires a company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances. The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. On July 9, 2015, the FASB approved a one-year deferral of the effective date so that the standard is effective for public entities for annual and interim periods beginning after December 15, 2017. The standard allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption where the standard is applied only to the most current period presented in the financial statements. Early adoption is permitted. Catalent is currently evaluating the impact of this standard on its consolidated results of operations and financial positio n.

Goodwill

Goodwill	3 Months Ended
	Sep. 30, 2015
Goodwill Disclosure [Abstract]
Goodwill	GOODWILL The following table summarizes the changes between June 30, 2015 and September 30, 2015 in the carrying amount of goodwill in total and by reporting segment: (Dollars in millions) Oral Technologies Medication Delivery Solutions Development & Clinical Services Total Balance at June 30, 2015 (1) $ 812.0 $ 19.9 $ 229.6 $ 1,061.5 Additions/(impairments) — — — — Foreign currency translation adjustments (17.5 ) — (5.9 ) (23.4 ) Balance at September 30, 2015 $ 794.5 $ 19.9 $ 223.7 $ 1,038.1 (1) The opening balance is reflective of prior impairment charges. No goodwill impairment charges were required during the current or comparable prior year period. When required, impairment charges are recorded within the consolidated statements of operations as impairment charges and (gain)/loss on sale of assets.

Definite Lived Long-Lived Asset

Definite Lived Long-Lived Assets	3 Months Ended
	Sep. 30, 2015
Intangible Assets Disclosure [Abstract]
Definite Lived Long-Lived Assets	DEFINITE LIVED LONG-LIVED ASSETS The Company’s definite-lived long-lived assets include property, plant and equipment as well as other intangible assets with definite lives. Refer to Note 15 Supplemental Balance Sheet Information for details related to property, plant and equipment. The details of other intangible assets subject to amortization as of September 30, 2015 and June 30, 2015 , are as follows: (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value September 30, 2015 Amortized intangibles: Core technology 18 years $ 175.1 $ (59.2 ) $ 115.9 Customer relationships 14 years 251.2 (84.5 ) 166.7 Product relationships 12 years 219.6 (154.1 ) 65.5 Total intangible assets $ 645.9 $ (297.8 ) $ 348.1 (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value June 30, 2015 Amortized intangibles: Core technology 18 years $ 177.6 $ (57.6 ) $ 120.0 Customer relationships 14 years 259.2 (81.8 ) 177.4 Product relationships 12 years 222.9 (151.6 ) 71.3 Total intangible assets $ 659.7 $ (291.0 ) $ 368.7 Amortization expense was $11.9 million and $11.3 million for the three months ended September 30, 2015 and September 30, 2014 , respectively. Future amortization expense for the next five years is estimated to be: (Dollars in millions) Remainder 2017 2018 2019 2020 2021 Amortization expense $ 35.3 $ 46.4 $ 46.4 $ 40.4 $ 25.7 $ 25.7

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-Term Obligations and Other Short-Term Borrowings	LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS Long-term obligations and other short-term borrowings consist of the following at September 30, 2015 and June 30, 2015 : (Dollars in millions) Maturity September 30, June 30, Senior Secured Credit Facilities Term loan facility dollar-denominated May 2021 $ 1,467.9 $ 1,471.0 Term loan facility euro-denominated May 2021 355.0 355.8 $200 million Revolving Credit Facility May 2019 — — Capital lease obligations 2020 to 2032 55.1 55.5 Other obligations 2016 to 2018 5.9 5.6 Total 1,883.9 1,887.9 Less: Current portion of long-term obligations and other short-term borrowings 24.0 23.8 Long-term obligations, less current portion $ 1,859.9 $ 1,864.1 Senior Secured Credit Facilities Borrowings under the term loan facilities and the revolving credit facility bear interest, at the Company’s option, at a rate equal to a margin over either (a) a base rate determined by reference to the higher of (1) the rate of interest published by The Wall Street Journal as its “prime lending rate” and (2) the federal funds rate plus one half of 1% or (b) a LIBOR rate determined by reference to the London Interbank Offered Rate set by ICE Benchmark Administration (or any successor thereto). The applicable margin for the term loans and borrowings under the revolving credit facility may be reduced subject to the Company attaining a certain total net leverage ratio. The applicable margin for borrowings is 3.50% for loans based on a LIBOR rate and 2.50% for loans based on base rate. The LIBOR rate for term loans is subject to a floor of 1.00% and the base rate for term loans is subject to a floor of 2.00% . Debt Covenants The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s (and the Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; enter into sale and leaseback transactions, amend material agreements governing the Company’s subordinated indebtedness and change the Company’s lines of business. The Credit Agreement also contains change of control provisions and certain customary affirmative covenants and events of default. The revolving credit facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of September 30, 2015 , the Company was in compliance with all material covenants related to its long-term obligations. Subject to certain exceptions, the Credit Agreement permits the Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of the Company’s non-U.S. subsidiaries or Puerto Rico subsidiaries is a guarantor of the loans. Under the Credit Agreement, the Company’s ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated EBITDA” in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement and is not defined under U.S. GAAP, and is subject to important limitations. Fair Value of Debt Measurements The estimated fair value of the long-term debt, which is considered a Level 2 liability, is based on the quoted market prices for the same or similar issues or on the current rates offered for debt of the same remaining maturities and considers collateral, if any. The carrying amounts and the estimated fair values of financial instruments as of September 30, 2015 and June 30, 2015 are as follows: September 30, 2015 June 30, 2015 (Dollars in millions) Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value Long-term debt and other $ 1,883.9 $ 1,851.2 $ 1,887.9 $ 1,854.7

Earnings Per Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2015 and 2014 are as follows (in millions, except per share data): Three Months Ended 2015 2014 Earnings / (loss) from continuing operations less net income / (loss) attributable to noncontrolling interest $ 9.1 $ (19.9 ) Earnings / (loss) from discontinued operations — 0.4 Net earnings / (loss) attributable to Catalent $ 9.1 $ (19.5 ) Weighted average shares outstanding 124,753,234 105,535,385 Dilutive securities issuable-stock plans 1,437,223 — Total weighted average diluted shares outstanding 126,190,457 105,535,385 Basic earnings per share of common stock: Earnings / (loss) from continuing operations $ 0.07 $ (0.19 ) Earnings / (loss) from discontinued operations — 0.01 Net earnings / (loss) attributable to Catalent $ 0.07 $ (0.18 ) Diluted earnings per share of common stock-assuming dilution: Earnings / (loss) from continuing operations $ 0.07 $ (0.19 ) Earnings / (loss) from discontinued operations — 0.01 Net earnings / (loss) attributable to Catalent $ 0.07 $ (0.18 ) The computation of diluted earnings per share for the three months ended September 30, 2015 excludes the effect of 2.1 million shares potentially issuable pursuant to awards granted under the 2007 Stock Incentive Plan, because the vesting provisions of those awards specify performance or market-based conditions that had not been met as of the period end. The computation of diluted earnings per share for the three months ended September 30, 2014 excludes the maximum effect of the potential common shares issuable under the employee stock option plan of approximately 6.8 million shares, and excludes restricted share awards of 1.4 million shares, because the Company had a net loss for the period and the effect would therefore be anti-dilutive.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	3 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Company is exposed to fluctuations in the applicable exchange rate on its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure of its investments in its European operations by denominating a portion of its debt in euros. At September 30, 2015 , the Company had euro-denominated debt outstanding of $355.0 million that qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portions of the translation gains or losses are reported in accumulated other comprehensive income/(loss) as part of the cumulative translation adjustment. The ineffective portions of the translation gains or losses are reported in the statement of operations. The following table includes net investment hedge activity during the three months ended September 30, 2015 and September 30, 2014 . The activity was not material during the three months ended September 30, 2015 . Three Months Ended (Dollars in millions) 2015 2014 Unrealized foreign exchange gain/(loss) within other comprehensive income $ — $ 10.8 Unrealized foreign exchange gain/(loss) within statement of operations $ — $ 21.3 The net accumulated gain of this net investment as of September 30, 2015 within other comprehensive income/(loss) was approximately $79.5 million . Amounts are reclassified out of accumulated other comprehensive income/(loss) into earnings when the entity to which the gains and losses reside is either sold or substantially liquidated.

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company accounts for income taxes in accordance with the provision of ASC 740 Income Taxes . Generally, fluctuations in the effective tax rate are primarily due to changes in U.S. and non-U.S. pretax income resulting from the Company’s business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. Such discrete items include, but are not limited to, changes in foreign statutory tax rates, the amortization of certain assets, changes in valuation allowance resulting from acquisition accounting and the tax impact of changes in its ASC 740 unrecognized tax benefit reserves. In the normal course of business, the Company is subject to examination by taxing authorities around the world, including such major jurisdictions as the United States, Germany, France, and the United Kingdom. The Company is no longer subject to non-U.S. income tax examinations for years prior to fiscal year 2006. Under the terms of the purchase agreement related to the 2007 acquisition, the Company is indemnified by its former owner for tax liabilities that may arise in the future that relate to tax periods prior to April 10, 2007. The indemnification agreement includes, among other taxes, any and all federal, state and international income-based taxes as well as related interest and penalties. As of September 30, 2015 and June 30, 2015 , approximately $2.3 million and $2.3 million , respectively, of unrecognized tax benefit is subject to indemnification by the Company's former owner. ASC 740 includes guidance on the accounting for uncertainty in income taxes recognized in the financial statements. This standard also provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeal or litigation process, based on the technical merits. As of September 30, 2015 , the Company had a total of $65.6 million of unrecognized tax benefits. A reconciliation of its reserves for uncertain tax positions, excluding accrued interest and penalties, for September 30, 2015 is as follows: (Dollars in millions) Balance at June 30, 2015 $ 66.9 Additions for tax positions of prior years 0.6 Reductions for tax positions of prior years (1.9 ) Balance at September 30, 2015 $ 65.6 As of September 30, 2015 and June 30, 2015 , the Company had a total of $72.7 million and $73.2 million , respectively, of uncertain tax positions (including accrued interest and penalties). As of these dates, $47.9 million and $48.7 million , respectively, represent the amount of unrecognized tax benefits, which, if recognized, would favorably affect the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of September 30, 2015 and June 30, 2015 , the Company has approximately $7.1 million and $6.3 million , respectively, of accrued interest and penalties related to uncertain tax positions. As of these dates, the portion of such interest and penalties subject to indemnification by its former owner is $2.3 million and $2.3 million , respectively.

Employee Retirement Benefit Pla

Employee Retirement Benefit Plans	3 Months Ended
	Sep. 30, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Employee Retirement Benefit Plans	EMPLOYEE RETIREMENT BENEFIT PLANS Components of the Company’s net periodic benefit costs are as follows: Three Months Ended (Dollars in millions) 2015 2014 Components of net periodic benefit cost: Service cost $ 0.7 $ 0.7 Interest cost 2.7 3.1 Expected return on plan assets (2.5 ) (2.8 ) Amortization (1) 0.7 0.5 Net amount recognized $ 1.6 $ 1.5 (1) Amount represents the amortization of unrecognized actuarial gains/(losses). As previously disclosed with regard to the Company’s participation in a multi-employer pension plan, the Company notified the plan trustees of its withdrawal from such plan in fiscal 2012. The actuarial review process, which is administered by the plan trustees, was completed during the third quarter of fiscal 2015 and the liability the Company has estimated reflects the present value of its expected future long-term obligations. The estimated discounted value of the projected contributions related to these plans is $39.4 million as of September 30, 2015 and $39.5 million as of June 30, 2015 . The annual cash impact associated with the Company's long-term obligation approximates $1.7 million per year.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS Advisor Transaction and Management Fees Prior to the IPO, the Company was party to a transaction and advisory fee agreement with affiliates of Blackstone and certain other investors in BHP PTS Holdings L.L.C. (the “Investors”), pursuant to which the Company historically paid an annual sponsor advisory fee to Blackstone and the Investors for certain monitoring, advisory and consulting services to the Company. In connection with the IPO, the Company paid the Investors an advisory agreement termination fee of $29.8 million in August 2014, which was recorded within other (income)/expense, net in the Consolidated Statements of Operations, and terminated the agreement.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	EQUITY AND ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Description of Capital Stock and Initial Public Offering The Company is authorized to issue 1,000,000,000 shares of common stock, par value $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. In accordance with the Company's amended and restated certificate of incorporation, each share of common stock has one vote, and the common stock votes together as a single class. In July 2014, the Company’s board of directors and holders of the requisite number of outstanding shares of its capital stock have approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 70 -for-1 stock split. The stock split became effective on July 17, 2014 upon the filing with the Delaware Secretary of State of an amendment to the Company's amended and restated certificate of incorporation. Refer to Note 1 for further discussion of the Company's July 2014 recapitalization and discussion of the Company's public offerings of common stock. Accumulated other comprehensive income/(loss) The components of the changes in the cumulative translation adjustment and minimum pension liability for the three months ended September 30, 2015 and September 30, 2014 are presented below. Three Months Ended (Dollars in millions) 2015 2014 Foreign currency translation adjustments: Net investment hedge $ — $ 10.8 Long term intercompany loans (14.2 ) (9.6 ) Translation adjustments (28.2 ) (55.4 ) Total foreign currency translation adjustment, pre tax (42.4 ) (54.2 ) Tax expense/(benefit) — (0.4 ) Total foreign currency translation adjustment, net of tax $ (42.4 ) $ (53.8 ) Net change in minimum pension liability Net gain/(loss) recognized during the period 0.7 0.5 Total pension, pretax 0.7 0.5 Tax expense/(benefit) (0.2 ) (0.1 ) Net change in minimum pension liability, net of tax $ 0.5 $ 0.4 For the three months ended September 30, 2015 the changes in accumulated other comprehensive income net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Other Post-Retirement Adjustments Deferred Compensation Total Balance at June 30, 2015 $ (130.0 ) $ (47.8 ) $ 3.8 $ (174.0 ) Other comprehensive income/(loss) before reclassifications (42.4 ) — (0.7 ) (43.1 ) Amounts reclassified from accumulated other comprehensive income — 0.5 — 0.5 Net current period other comprehensive income (loss) (42.4 ) 0.5 (0.7 ) (42.6 ) Balance at September 30, 2015 $ (172.4 ) $ (47.3 ) $ 3.1 $ (216.6 )

Other Income _ Expense

Other Income / Expense	3 Months Ended
	Sep. 30, 2015
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	OTHER (INCOME) / EXPENSE, NET The components of Other (Income) / Expense, net for the three months ended September 30, 2015 and 2014 are as follows: Three Months Ended (Dollars in millions) 2015 2014 Other (income) / expense, net Debt extinguishment costs $ — $ 20.6 (Gain) / loss on acquisition (1) — (7.0 ) Sponsor advisory agreement termination fee (2) — 29.8 Foreign currency (gains) and losses — (3.1 ) Other 0.6 1.0 Total Other (Income) / Expense $ 0.6 $ 41.3 (1) During the three months ended September 30, 2014, the Company recorded a $7.0 million bargain purchase gain for an acquisition completed in July 2014. (2) The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO. Refer to Note 9 for further discussion.

Redeemable noncontrolling inter

Redeemable noncontrolling interest	3 Months Ended
	Sep. 30, 2015
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	REDEEMABLE NONCONTROLLING INTEREST In July 2013, the Company acquired a 67% controlling interest in a softgel manufacturing facility located in Haining, China. The noncontrolling interest shareholders have the right to jointly sell the remaining 33% interest to Catalent during the 30-day period following the third anniversary of closing for a price based on the greater of (1) an amount that would provide the noncontrolling interest shareholders a return on their investment of a predetermined amount per annum on their pro rata share of the initial valuation or (2) a multiple of the sum of the target's earnings before interest, taxes, depreciation and amortization and amortization less net debt for the four quarters immediately preceding such sale. Noncontrolling interest with redemption features, such as the arrangement described above, that are not solely within the Company's control are considered redeemable noncontrolling interests, which is considered temporary equity and is therefore reported outside of permanent equity on the Company's consolidated balance sheet at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net income/(loss) or its redemption value. In June 2015, the Company reached an agreement to acquire the remaining 33% from the noncontrolling interest shareholders for purchase consideration of $5.8 million . The transaction is expected to close in fiscal 2016 after customary closing conditions are met, including regulatory approvals.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. From time to time, the Company receives subpoenas or requests for information from various government agencies, including from state attorneys general and the U.S. Department of Justice relating to the business practices of customers or suppliers. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. The Company expects to incur costs in future periods in connection with future requests.

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company conducts its business within the following operating segments: Softgel Technologies, Modified Release Technologies, Medication Delivery Solutions and Development and Clinical Services. The Softgel Technologies and Modified Release Technologies segments are aggregated into one reportable operating segment – Oral Technologies. The Company evaluates the performance of its segments based on segment earnings before noncontrolling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization (“Segment EBITDA”). EBITDA from continuing operations is consolidated earnings from continuing operations before interest expense, income tax (benefit)/expense, depreciation and amortization and is adjusted for the income or loss attributable to noncontrolling interest. The Company’s presentation of Segment EBITDA and EBITDA from continuing operations may not be comparable to similarly titled measures used by other companies. The following tables include net revenue and Segment EBITDA during the three months ended September 30, 2015 and September 30, 2014 : Three Months Ended (Dollars in millions) 2015 2014 Oral Technologies Net revenue $ 247.7 $ 261.1 Segment EBITDA 51.1 57.7 Medication Delivery Solutions Net revenue 55.7 56.9 Segment EBITDA 7.8 9.9 Development and Clinical Services Net revenue 122.9 103.1 Segment EBITDA 27.2 21.4 Inter-segment revenue elimination (3.3 ) (2.8 ) Unallocated Costs (1) (13.9 ) (52.4 ) Combined Totals: Net revenue $ 423.0 $ 418.3 EBITDA from continuing operations $ 72.2 $ 36.6 (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: Three Months Ended (Dollars in millions) 2015 2014 Impairment charges and gain/(loss) on sale of assets $ (1.2 ) $ — Equity compensation $ (2.5 ) $ (1.5 ) Restructuring and other special items (2) (2.0 ) (4.5 ) Noncontrolling interest 0.2 0.4 Other income/(expense), net (3) (0.6 ) (41.3 ) Non-allocated corporate costs, net (7.8 ) (5.5 ) Total unallocated costs $ (13.9 ) $ (52.4 ) (2) Segment results do not include restructuring and certain acquisition-related costs. (3) Amounts primarily relate to foreign currency translation gains and losses during all periods presented. Prior period amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million , offset by an acquisition-related gain of $7.0 million . Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations: Three Months Ended (Dollars in millions) 2015 2014 Earnings/(loss) from continuing operations $ 8.9 $ (20.3 ) Depreciation and amortization 35.5 35.0 Interest expense, net 22.7 35.5 Income tax (benefit)/expense 4.9 (14.0 ) Noncontrolling interest 0.2 0.4 EBITDA from continuing operations $ 72.2 $ 36.6 The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: (Dollars in millions) September 30, June 30, Assets Oral Technologies $ 2,426.3 $ 2,477.3 Medication Delivery Solutions 242.7 247.8 Development and Clinical Services 688.5 703.2 Corporate and eliminations (301.1 ) (282.9 ) Total assets $ 3,056.4 $ 3,145.4

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Sep. 30, 2015
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	SUPPLEMENTAL BALANCE SHEET INFORMATION Supplementary balance sheet information at September 30, 2015 and June 30, 2015 is detailed in the following tables. Inventories Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) September 30, June 30, Raw materials and supplies $ 89.6 $ 76.9 Work-in-process 28.2 26.3 Finished goods 46.5 43.8 Total inventories, gross 164.3 147.0 Inventory reserve (13.4 ) (14.1 ) Inventories $ 150.9 $ 132.9 Prepaid expenses and other Prepaid expenses and other current assets consist of the following: (Dollars in millions) September 30, June 30, Prepaid expenses $ 27.5 $ 22.0 Spare parts supplies 11.2 11.5 Deferred taxes 14.8 19.7 Other current assets 27.2 27.7 Prepaid expenses and other $ 80.7 $ 80.9 Property, plant, and equipment, net Property, plant, and equipment, net consist of the following: (Dollars in millions) September 30, June 30, Land, buildings, and improvements $ 639.0 $ 637.6 Machinery, equipment, and capitalized software 728.8 727.9 Furniture and fixtures 10.6 10.1 Construction in progress 109.5 97.6 Property, plant, and equipment, at cost 1,487.9 1,473.2 Accumulated depreciation (603.6 ) (588.0 ) Property, plant, and equipment, net $ 884.3 $ 885.2 Other assets Other assets consist of the following: (Dollars in millions) September 30, June 30, Deferred long term debt financing costs $ 9.1 $ 9.5 Other 18.1 18.9 Total other assets $ 27.2 $ 28.4 Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) September 30, June 30, Accrued employee-related expenses $ 60.6 $ 87.8 Restructuring accrual 6.5 7.3 Deferred income tax 1.4 1.5 Accrued interest 0.3 0.2 Deferred revenue and fees 38.0 39.0 Accrued income tax 43.7 55.8 Other accrued liabilities and expenses 51.0 55.4 Other accrued liabilities $ 201.5 $ 247.0

Subsequent Events Subsequent Ev

Subsequent Events Subsequent Events	3 Months Ended
	Sep. 30, 2015
Subsequent Event [Line Items]
Subsequent Events [Text Block]	On October 29, 2015, the Company’s Board of Directors authorized a share repurchase program to use up to $100.0 million to repurchase shares of its outstanding common stock. Under the program, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions or otherwise as permitted by applicable federal securities laws.

Basis of Presentation and Sum25

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending June 30, 2016 . The consolidated balance sheet at June 30, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015 filed with the SEC. Noncontrolling interest is included within the equity section in the consolidated balance sheets. Redeemable noncontrolling interest has been classified as temporary equity and is therefore reported outside of permanent equity on the consolidated balance sheets at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net earnings/(loss) or its redemption value. The Company presents the amount of consolidated net earnings/(loss) that is attributable to Catalent and the noncontrolling interest in the consolidated statements of operations. Furthermore, the Company discloses the amount of comprehensive income that is attributable to Catalent and the noncontrolling interest in the consolidated statements of comprehensive income/(loss).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative financial instruments and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.
Translation and Transaction of Foreign Currencies	Foreign Currency Translation The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. The currency fluctuations related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the consolidated statements of operations in the other (income) expense, net line item. Foreign currency translation gains and losses generated from inter-company loans that are long-term in nature, but may be repayable in the foreseeable future, are also recorded within the other (income)/expense, net line item on the consolidated statements of operations.
Revenue Recognition	Revenue Recognition In accordance with Codification Standard ASC 605 Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. In cases where the Company has multiple contracts with the same customer, the Company evaluates those contracts to assess if the contracts are linked or are separate arrangements. Factors the Company considers include the timing of negotiation, interdependency with other contracts or elements and payment terms. The Company and its customers generally view each contract discussion as a separate arrangement. Manufacturing and packaging service revenue is recognized upon delivery of the product in accordance with the terms of the contract, which specify when transfer of title and risk of loss occurs. Some of the Company’s manufacturing contracts with its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the unfilled purchase obligation in accordance with the contract terms. Development service contracts generally take the form of a fee-for-service arrangement. After the Company has evidence of an arrangement, the price is determinable and there is a reasonable expectation regarding payment, the Company recognizes revenue at the point in time the service obligation is completed and accepted by the customer. Examples of output measures include a formulation report, analytical and stability testing, clinical batch production or packaging and the storage and distribution of a customer’s clinical trial material. Development service revenue is primarily driven by the Company’s Development and Clinical Services segment. Arrangements containing multiple elements, including service arrangements, are accounted for in accordance with the provisions of ASC 605-25 Revenue Recognition: Multiple-Element Arrangements . The Company determines the separate units of account in accordance with ASC 605-25. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price.
Goodwill	Goodwill The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350 Goodwill, Intangible and Other Assets . Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company's annual goodwill impairment test was conducted as of April 1, 2015. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. In addition, the Company uses comparative market information and other factors to corroborate the discounted cash flow results.
Property and Equipment	Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following ranges of useful lives for its property and equipment categories: buildings and improvements - 5 to 50 years; machinery and equipment - 3 to 10 years; and furniture and fixtures - 3 to 7 years. Depreciation expense was $23.6 million for the three months ended September 30, 2015 and $23.7 million for the three months ended September 30, 2014 , respectively. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented.
Intangible Assets, Finite-Lived, Policy	Intangible assets with finite lives, primarily including customer relationships and patents and trademarks continue to be amortized over their useful lives. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment . This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm's length transactions.
Research and Development Expense, Policy	Research and Development Costs The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general and administrative expenses. Such research and development costs included in selling, general and administrative expenses amounted to $1.6 million for the three months ended September 30, 2015 , and $2.8 million for the three months ended September 30, 2014 . Costs incurred in connection with research and development services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $11.8 million for the three months ended September 30, 2015 and $8.8 million for the three months ended September 30, 2014 , respectively.
Earnings Per Share, Policy	Earnings / (Loss) Per Share The Company reports net earnings/(loss) per share pursuant to ASC 260 Earnings per Share . Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net earnings or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net earnings or loss available to common stockholders by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share includes in-the-money stock options, restricted stock units, and restricted stock using the treasury stock method. During a loss period, the assumed exercise of in-the-money stock options has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share.
Share-based Compensation, Option and Incentive Plans Policy	Equity-Based Compensation The Company accounts for its equity-based compensation awards pursuant to ASC 718 Compensation-Stock Compensation . ASC 718 requires companies to recognize compensation expense using a fair value based method for costs related to share-based payments including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards that are expected to vest, and the expense is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate. The terms of the Company’s equity-based compensation plans permit shares that are issued upon an employee's exercise of an option to be withheld through a net settlement transaction as a means of meeting tax withholding requirements.
Recent Financial Accounting Standards	Recent Financial Accounting Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2015-16, Simplifying the Accounting for Measurement Period Adjustments. The new standard eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment be recognized in the reporting period in which the adjustment is identified. The standard is effective for public entities for annual periods beginning after December 15, 2017. Early adoption is permitted. Catalent has determined the impact of this standard will be not be material on its consolidated results of operations and financial positio n. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . The new standard requires that debt issuance costs be presented in the balance sheet as a direct reduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The standard is effective for public entities for annual and interim periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. Catalent has determined the impact of this standard will be not be material on its consolidated results of operations and financial positio n. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers . The new standard will supersede nearly all existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the standard creates a five-step model that requires a company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances. The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. On July 9, 2015, the FASB approved a one-year deferral of the effective date so that the standard is effective for public entities for annual and interim periods beginning after December 15, 2017. The standard allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption where the standard is applied only to the most current period presented in the financial statements. Early adoption is permitted. Catalent is currently evaluating the impact of this standard on its consolidated results of operations and financial positio n.

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Sep. 30, 2015
Goodwill Disclosure [Abstract]
Goodwill - Rollforward	The following table summarizes the changes between June 30, 2015 and September 30, 2015 in the carrying amount of goodwill in total and by reporting segment: (Dollars in millions) Oral Technologies Medication Delivery Solutions Development & Clinical Services Total Balance at June 30, 2015 (1) $ 812.0 $ 19.9 $ 229.6 $ 1,061.5 Additions/(impairments) — — — — Foreign currency translation adjustments (17.5 ) — (5.9 ) (23.4 ) Balance at September 30, 2015 $ 794.5 $ 19.9 $ 223.7 $ 1,038.1 (1) The opening balance is reflective of prior impairment charges.

Definite Lived Long-Lived Ass27

Definite Lived Long-Lived Assets (Tables)	3 Months Ended
	Sep. 30, 2015
Intangible Assets Disclosure [Abstract]
Other Intangible Assets Subject to Amortization	The details of other intangible assets subject to amortization as of September 30, 2015 and June 30, 2015 , are as follows: (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value September 30, 2015 Amortized intangibles: Core technology 18 years $ 175.1 $ (59.2 ) $ 115.9 Customer relationships 14 years 251.2 (84.5 ) 166.7 Product relationships 12 years 219.6 (154.1 ) 65.5 Total intangible assets $ 645.9 $ (297.8 ) $ 348.1 (Dollars in millions) Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value June 30, 2015 Amortized intangibles: Core technology 18 years $ 177.6 $ (57.6 ) $ 120.0 Customer relationships 14 years 259.2 (81.8 ) 177.4 Product relationships 12 years 222.9 (151.6 ) 71.3 Total intangible assets $ 659.7 $ (291.0 ) $ 368.7
Future Amortization Expense	Future amortization expense for the next five years is estimated to be: (Dollars in millions) Remainder 2017 2018 2019 2020 2021 Amortization expense $ 35.3 $ 46.4 $ 46.4 $ 40.4 $ 25.7 $ 25.7

Long-Term Obligations and Oth28

Long-Term Obligations and Other Short-Term Borrowings (Tables)	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings	Long-term obligations and other short-term borrowings consist of the following at September 30, 2015 and June 30, 2015 : (Dollars in millions) Maturity September 30, June 30, Senior Secured Credit Facilities Term loan facility dollar-denominated May 2021 $ 1,467.9 $ 1,471.0 Term loan facility euro-denominated May 2021 355.0 355.8 $200 million Revolving Credit Facility May 2019 — — Capital lease obligations 2020 to 2032 55.1 55.5 Other obligations 2016 to 2018 5.9 5.6 Total 1,883.9 1,887.9 Less: Current portion of long-term obligations and other short-term borrowings 24.0 23.8 Long-term obligations, less current portion $ 1,859.9 $ 1,864.1

Long-Term Obligations and Oth29

Long-Term Obligations and Other Short-Term Borrowings Fair Value of Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule Of Carrying And Fair Value Of Financial Instruments Table	The carrying amounts and the estimated fair values of financial instruments as of September 30, 2015 and June 30, 2015 are as follows: September 30, 2015 June 30, 2015 (Dollars in millions) Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value Long-term debt and other $ 1,883.9 $ 1,851.2 $ 1,887.9 $ 1,854.7

Earnings Per Share Earnings Per

Earnings Per Share Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2015 and 2014 are as follows (in millions, except per share data): Three Months Ended 2015 2014 Earnings / (loss) from continuing operations less net income / (loss) attributable to noncontrolling interest $ 9.1 $ (19.9 ) Earnings / (loss) from discontinued operations — 0.4 Net earnings / (loss) attributable to Catalent $ 9.1 $ (19.5 ) Weighted average shares outstanding 124,753,234 105,535,385 Dilutive securities issuable-stock plans 1,437,223 — Total weighted average diluted shares outstanding 126,190,457 105,535,385 Basic earnings per share of common stock: Earnings / (loss) from continuing operations $ 0.07 $ (0.19 ) Earnings / (loss) from discontinued operations — 0.01 Net earnings / (loss) attributable to Catalent $ 0.07 $ (0.18 ) Diluted earnings per share of common stock-assuming dilution: Earnings / (loss) from continuing operations $ 0.07 $ (0.19 ) Earnings / (loss) from discontinued operations — 0.01 Net earnings / (loss) attributable to Catalent $ 0.07 $ (0.18 )

Derivative Instruments and He31

Derivative Instruments and Hedging Activities Net Investment Hedge Activity (Tables)	3 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance	The following table includes net investment hedge activity during the three months ended September 30, 2015 and September 30, 2014 . The activity was not material during the three months ended September 30, 2015 . Three Months Ended (Dollars in millions) 2015 2014 Unrealized foreign exchange gain/(loss) within other comprehensive income $ — $ 10.8 Unrealized foreign exchange gain/(loss) within statement of operations $ — $ 21.3

Income Taxes Income Taxes (Tabl

Income Taxes Income Taxes (Tables)	3 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward	A reconciliation of its reserves for uncertain tax positions, excluding accrued interest and penalties, for September 30, 2015 is as follows: (Dollars in millions) Balance at June 30, 2015 $ 66.9 Additions for tax positions of prior years 0.6 Reductions for tax positions of prior years (1.9 ) Balance at September 30, 2015 $ 65.6

Employee Retirement Benefit P33

Employee Retirement Benefit Plans (Tables)	3 Months Ended
	Sep. 30, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Components of Company's Net Periodic Benefit Costs	Components of the Company’s net periodic benefit costs are as follows: Three Months Ended (Dollars in millions) 2015 2014 Components of net periodic benefit cost: Service cost $ 0.7 $ 0.7 Interest cost 2.7 3.1 Expected return on plan assets (2.5 ) (2.8 ) Amortization (1) 0.7 0.5 Net amount recognized $ 1.6 $ 1.5 (1) Amount represents the amortization of unrecognized actuarial gains/(losses).

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Comprehensive Income (Loss)	The components of the changes in the cumulative translation adjustment and minimum pension liability for the three months ended September 30, 2015 and September 30, 2014 are presented below. Three Months Ended (Dollars in millions) 2015 2014 Foreign currency translation adjustments: Net investment hedge $ — $ 10.8 Long term intercompany loans (14.2 ) (9.6 ) Translation adjustments (28.2 ) (55.4 ) Total foreign currency translation adjustment, pre tax (42.4 ) (54.2 ) Tax expense/(benefit) — (0.4 ) Total foreign currency translation adjustment, net of tax $ (42.4 ) $ (53.8 ) Net change in minimum pension liability Net gain/(loss) recognized during the period 0.7 0.5 Total pension, pretax 0.7 0.5 Tax expense/(benefit) (0.2 ) (0.1 ) Net change in minimum pension liability, net of tax $ 0.5 $ 0.4
Schedule of Accumulated Other Comprehensive Income (Loss)	ated other comprehensive income net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Other Post-Retirement Adjustments Deferred Compensation Total Balance at June 30, 2015 $ (130.0 ) $ (47.8 ) $ 3.8 $ (174.0 ) Other comprehensive income/(loss) before reclassifications (42.4 ) — (0.7 ) (43.1 ) Amounts reclassified from accumulated other comprehensive income — 0.5 — 0.5 Net current period other comprehensive income (loss) (42.4 ) 0.5 (0.7 ) (42.6 ) Balance at September 30, 2015 $ (172.4 ) $ (47.3 ) $ 3.1 $ (216.6 )

Other Income _ Expense (Tables)

Other Income / Expense (Tables)	3 Months Ended
	Sep. 30, 2015
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating (Income) Expense	The components of Other (Income) / Expense, net for the three months ended September 30, 2015 and 2014 are as follows: Three Months Ended (Dollars in millions) 2015 2014 Other (income) / expense, net Debt extinguishment costs $ — $ 20.6 (Gain) / loss on acquisition (1) — (7.0 ) Sponsor advisory agreement termination fee (2) — 29.8 Foreign currency (gains) and losses — (3.1 ) Other 0.6 1.0 Total Other (Income) / Expense $ 0.6 $ 41.3 (1) During the three months ended September 30, 2014, the Company recorded a $7.0 million bargain purchase gain for an acquisition completed in July 2014. (2) The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Net Revenue and Segment EBITDA	The following tables include net revenue and Segment EBITDA during the three months ended September 30, 2015 and September 30, 2014 : Three Months Ended (Dollars in millions) 2015 2014 Oral Technologies Net revenue $ 247.7 $ 261.1 Segment EBITDA 51.1 57.7 Medication Delivery Solutions Net revenue 55.7 56.9 Segment EBITDA 7.8 9.9 Development and Clinical Services Net revenue 122.9 103.1 Segment EBITDA 27.2 21.4 Inter-segment revenue elimination (3.3 ) (2.8 ) Unallocated Costs (1) (13.9 ) (52.4 ) Combined Totals: Net revenue $ 423.0 $ 418.3 EBITDA from continuing operations $ 72.2 $ 36.6 (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: Three Months Ended (Dollars in millions) 2015 2014 Impairment charges and gain/(loss) on sale of assets $ (1.2 ) $ — Equity compensation $ (2.5 ) $ (1.5 ) Restructuring and other special items (2) (2.0 ) (4.5 ) Noncontrolling interest 0.2 0.4 Other income/(expense), net (3) (0.6 ) (41.3 ) Non-allocated corporate costs, net (7.8 ) (5.5 ) Total unallocated costs $ (13.9 ) $ (52.4 ) (2) Segment results do not include restructuring and certain acquisition-related costs. (3) Amounts primarily relate to foreign currency translation gains and losses during all periods presented. Prior period amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million , offset by an acquisition-related gain of $7.0 million .
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA	Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations: Three Months Ended (Dollars in millions) 2015 2014 Earnings/(loss) from continuing operations $ 8.9 $ (20.3 ) Depreciation and amortization 35.5 35.0 Interest expense, net 22.7 35.5 Income tax (benefit)/expense 4.9 (14.0 ) Noncontrolling interest 0.2 0.4 EBITDA from continuing operations $ 72.2 $ 36.6
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: (Dollars in millions) September 30, June 30, Assets Oral Technologies $ 2,426.3 $ 2,477.3 Medication Delivery Solutions 242.7 247.8 Development and Clinical Services 688.5 703.2 Corporate and eliminations (301.1 ) (282.9 ) Total assets $ 3,056.4 $ 3,145.4

Supplemental Balance Sheet In37

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Sep. 30, 2015
Balance Sheet Related Disclosures [Abstract]
Inventory	Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) September 30, June 30, Raw materials and supplies $ 89.6 $ 76.9 Work-in-process 28.2 26.3 Finished goods 46.5 43.8 Total inventories, gross 164.3 147.0 Inventory reserve (13.4 ) (14.1 ) Inventories $ 150.9 $ 132.9
Prepaid and Other Assets	Prepaid expenses and other current assets consist of the following: (Dollars in millions) September 30, June 30, Prepaid expenses $ 27.5 $ 22.0 Spare parts supplies 11.2 11.5 Deferred taxes 14.8 19.7 Other current assets 27.2 27.7 Prepaid expenses and other $ 80.7 $ 80.9
Property and Equipment	Property, plant, and equipment, net consist of the following: (Dollars in millions) September 30, June 30, Land, buildings, and improvements $ 639.0 $ 637.6 Machinery, equipment, and capitalized software 728.8 727.9 Furniture and fixtures 10.6 10.1 Construction in progress 109.5 97.6 Property, plant, and equipment, at cost 1,487.9 1,473.2 Accumulated depreciation (603.6 ) (588.0 ) Property, plant, and equipment, net $ 884.3 $ 885.2
Other Assets Non Current	Other assets consist of the following: (Dollars in millions) September 30, June 30, Deferred long term debt financing costs $ 9.1 $ 9.5 Other 18.1 18.9 Total other assets $ 27.2 $ 28.4
Other Accrued Liabilities	Other accrued liabilities consist of the following: (Dollars in millions) September 30, June 30, Accrued employee-related expenses $ 60.6 $ 87.8 Restructuring accrual 6.5 7.3 Deferred income tax 1.4 1.5 Accrued interest 0.3 0.2 Deferred revenue and fees 38.0 39.0 Accrued income tax 43.7 55.8 Other accrued liabilities and expenses 51.0 55.4 Other accrued liabilities $ 201.5 $ 247.0

Basis of Presentation and Sum38

Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies - Business (Details) $ / shares in Units, shares in Millions, $ in Millions		Jun. 02, 2015$ / sharesshares	Mar. 09, 2015$ / sharesshares	Jul. 17, 2014	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)shares	Jul. 31, 2014$ / shares
Stockholders' Equity Note, Stock Split, Conversion Ratio				70
Stock Issued During Period, Shares, New Issues						48.9
Share Price | $ / shares							$ 20.50
Proceeds from Issuance Initial Public Offering | $						$ 952.2
(Gain) / Loss on Contract Termination | $	[1]				$ 0	$ 29.8
Sale of Stock, Number of Shares, Underwriters Option to Purchase		2.1	3.6
Blackstone [Member]
Share Price | $ / shares		$ 29	$ 29.50
Sale of Stock, Number of Shares Sold by Entity		16.1	27.3
Noncontrolling Interest, Ownership Percentage by Parent		20.80%	32.70%
[1]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.

Basis of Presentation and Sum39

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 23.6	$ 23.7
Building And Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	5 years
Building And Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	50 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	7 years

Basis of Presentation and Sum40

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Selling, General and Administrative Expenses [Member]
Research and Development Expense [Line Items]
Research and Development Expense	$ 1.6	$ 2.8
Cost of Sales [Member]
Research and Development Expense [Line Items]
Research and Development Expense	$ 11.8	$ 8.8

Goodwill - Rollforward (Detail)

Goodwill - Rollforward (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 1,061.5	[1]
Additions/(impairments)	0
Foreign currency translation adjustments	(23.4)
Ending balance	1,038.1
Oral Technologies [Member]
Goodwill [Roll Forward]
Beginning balance	812	[1]
Additions/(impairments)	0
Foreign currency translation adjustments	(17.5)
Ending balance	794.5
Medication Delivery Solutions [Member]
Goodwill [Roll Forward]
Beginning balance	19.9	[1]
Additions/(impairments)	0
Foreign currency translation adjustments	0
Ending balance	19.9
Development and Clinical Services [Member]
Goodwill [Roll Forward]
Beginning balance	229.6	[1]
Additions/(impairments)	0
Foreign currency translation adjustments	(5.9)
Ending balance	$ 223.7
[1]	The opening balance is reflective of prior impairment charges.

Definite Lived Long-Lived Ass42

Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 11.9	$ 11.3
Gross Carrying Value	645.9		$ 659.7
Accumulated Amortization	(297.8)		(291)
Net Carrying Value	$ 348.1		$ 368.7
Core technology [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	18 years		18 years
Gross Carrying Value	$ 175.1		$ 177.6
Accumulated Amortization	(59.2)		(57.6)
Net Carrying Value	$ 115.9		$ 120
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years		14 years
Gross Carrying Value	$ 251.2		$ 259.2
Accumulated Amortization	(84.5)		(81.8)
Net Carrying Value	$ 166.7		$ 177.4
Product relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years		12 years
Gross Carrying Value	$ 219.6		$ 222.9
Accumulated Amortization	(154.1)		(151.6)
Net Carrying Value	$ 65.5		$ 71.3

Definite Lived Long-Lived Ass43

Definite Lived Long-Lived Assets - Future Amortization Expense (Detail) $ in Millions	Sep. 30, 2015USD ($)
Intangible Assets Disclosure [Abstract]
Remainder Fiscal 2016	$ 35.3
2,017	46.4
2,018	46.4
2,019	40.4
2,020	25.7
2,021	$ 25.7

Long-Term Obligations and Oth44

Long-Term Obligations and Other Short-Term Borrowings - Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Schedule Of Debt [Line Items]
Debt, Current	$ 24	$ 23.8
Long-term Debt and Capital Lease Obligations	1,859.9	1,864.1
Term Loan Three Facility Dollar Denominated [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations	1,467.9	1,471
Term Loan Three Facility Euro Denominated [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations	355	355.8
Revolving Credit Facility - Two [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations	0	0
Capital Lease Obligations [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations	55.1	55.5
Other Obligations [Member]
Schedule Of Debt [Line Items]
Debt and Capital Lease Obligations	$ 5.9	$ 5.6

Long-Term Obligations and Oth45

Long-Term Obligations and Other Short-Term Borrowings Long-Term Obligations and Other Short-Term Borrowings - Interest Rate (Details)	3 Months Ended
	Sep. 30, 2015
London Interbank Offered Rate (LIBOR) [Member] | Term Loan Three Facility Dollar Denominated [Member]
Debt Instrument, Basis Spread on Variable Rate	3.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	1.00%
London Interbank Offered Rate (LIBOR) [Member] | Term Loan Three Facility Euro Denominated [Member]
Debt Instrument, Basis Spread on Variable Rate	3.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	1.00%
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility - Two [Member]
Debt Instrument, Basis Spread on Variable Rate	3.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	1.00%
Base Rate [Member] | Term Loan Three Facility Dollar Denominated [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	2.00%
Base Rate [Member] | Term Loan Three Facility Euro Denominated [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	2.00%
Base Rate [Member] | Revolving Credit Facility - Two [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	2.00%

Long-Term Obligations and Oth46

Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of FInancial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt and Capital Lease Obligations	$ 1,883.9	$ 1,887.9
Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	$ 1,851.2	$ 1,854.7

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Earnings/(loss) from continuing operations less net earnings (loss) attributable to noncontrolling interest	$ 9.1	$ (19.9)
Net earnings/(loss) from discontinued operations, net of tax	0	0.4
Net Income (Loss) Attributable to Parent	$ 9.1	$ (19.5)
Weighted Average Number of Shares Outstanding, Basic	124,753,234	105,535,385
Weighted Average Number Diluted Shares Outstanding Adjustment	1,437,223	0
Weighted Average Number of Shares Outstanding, Diluted	126,190,457	105,535,385
Income (Loss) from Continuing Operations, Per Basic Share	$ 0.07	$ (0.19)
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	0	0.01
Earnings Per Share, Basic	0.07	(0.18)
Income (Loss) from Continuing Operations, Per Diluted Share	0.07	(0.19)
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	0	0.01
Earnings Per Share, Diluted	$ 0.07	$ (0.18)

Earnings Per Share Earnings P48

Earnings Per Share Earnings Per Share - Additional Details (Details) - Stock Compensation Plan [Member] - shares shares in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2.1	6.8
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1.4

Derivative Instruments and He49

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Derivative [Line Items]
Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)	$ 0	$ 10.8
Unrealized foreign exchange gain(loss)	0	$ 21.3
Net accumulated gain related to investment hedges	79.5
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Total long-term debt	$ 355

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 65.6	$ 66.9
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued	72.7	73.2
Unrecognized tax benefits that impact the effective income tax rate	47.9	48.7
Accrued interest related to uncertain tax positions	7.1	6.3
Interest and penalties subject to indemnification	2.3	2.3
Former Owner [Member]
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits Subject to Indemnification	$ 2.3	$ 2.3

Income Taxes Income Tax Disclos

Income Taxes Income Tax Disclosure (Details) $ in Millions	3 Months Ended
	Sep. 30, 2015USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 66.9
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions	0.6
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions	(1.9)
Ending Balance	$ 65.6

Employee Retirement Benefit P52

Employee Retirement Benefit Plans - Components of Company's Net Periodic Benefit Costs (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Components of net periodic benefit cost:
Service cost		$ 0.7	$ 0.7
Interest cost		2.7	3.1
Expected return on plan assets		(2.5)	(2.8)
Amortization	[1]	0.7	0.5
Net amount recognized		1.6	$ 1.5
Estimated discounted value of future employer contributions		39.4		$ 39.5
Estimated annual cash contribution		$ 1.7
[1]	Amount represents the amortization of unrecognized actuarial gains/(losses).

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended
		Sep. 30, 2015	Sep. 30, 2014
(Gain) / Loss on Contract Termination	[1]	$ 0	$ 29.8
[1]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.

Equity and Accumulated Other Co

Equity and Accumulated Other Comprehensive Income (Loss) Equity	Jul. 17, 2014	Sep. 30, 2015$ / sharesshares	Jun. 30, 2015$ / sharesshares
Equity [Abstract]
Common Stock, Shares Authorized | shares		1,000,000,000	1,000,000,000
Common Stock, Par or Stated Value Per Share		$ 0.01	$ 0.01
Preferred Stock, Shares Authorized | shares		100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.01
Stockholders' Equity Note, Stock Split, Conversion Ratio	70

Accumulated Other Comprehensi55

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Foreign currency translation adjustments:
Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)	$ 0	$ 10.8
Long term intercompany loans	(14.2)	(9.6)
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	(28.2)	(55.4)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax	(42.4)	(54.2)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	0	(0.4)
Total foreign currency translation adjustment, pre tax	(42.4)	(53.8)
Net change in minimum pension liability
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax	0.7	0.5
Total pension, pretax	0.7	0.5
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(0.2)	(0.1)
Net change in minimum pension liability, net of tax	$ 0.5	$ 0.4

Accumulated Other Comprehensi56

Accumulated Other Comprehensive Income (Loss)-Rollforward (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ (174)
Other comprehensive income/(loss) before reclassifications	(43.1)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(0.5)
Net current period other comprehensive income (loss)	(42.6)	$ (53.6)
Ending Balance	(216.6)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(130)
Other comprehensive income/(loss) before reclassifications	(42.4)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0
Net current period other comprehensive income (loss)	(42.4)
Ending Balance	(172.4)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(47.8)
Other comprehensive income/(loss) before reclassifications	0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(0.5)
Net current period other comprehensive income (loss)	0.5
Ending Balance	(47.3)
Accumulated Deferred Compensation [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	3.8
Other comprehensive income/(loss) before reclassifications	(0.7)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0
Net current period other comprehensive income (loss)	(0.7)
Ending Balance	$ 3.1

Other Income _ Expense Other In

Other Income / Expense Other Income / Expense (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended
		Jul. 31, 2014	[1]	Sep. 30, 2015		Sep. 30, 2014
Other Income and Expenses [Abstract]
Extinguishment of Debt, Gain (Loss), Net of Tax				$ 0		$ (20.6)
Business Combination, Bargain Purchase, Gain Recognized, Amount Net of Tax		$ (7)		0	[1]	(7)
(Gain) / Loss on Contract Termination	[2]			0		29.8
Foreign Currency Transaction (Gain) / Loss, Unrealized				0		(3.1)
Other Nonoperating (Income) Expense				0.6		1
Nonoperating Income (Expense)				$ (0.6)		$ (41.3)
[1]	During the three months ended September 30, 2014, the Company recorded a $7.0 million bargain purchase gain for an acquisition completed in July 2014.
[2]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.

Redeemable noncontrolling int58

Redeemable noncontrolling interest (Details) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015	Jul. 31, 2013
Business Acquisition [Line Items]
Redeemable Noncontrolling Interest, Equity, Carrying Amount	$ 5.8	$ 5.8
Softgel Manufacturing Facility [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			67.00%
Ownership percentage by noncontrolling owners (percent)			33.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Estimated annual cash contribution	$ 1.7

Segment Information - Net Reven

Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		1 Months Ended		3 Months Ended
		Jul. 31, 2014	[5]	Sep. 30, 2015		Sep. 30, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue				$ 423		$ 418.3
Segment EBITDA				72.2		36.6
Inter-segment revenue elimination				(3.3)		(2.8)
Unallocated Costs	[1]			(13.9)		(52.4)
Impairment Charges And Gain Loss On Sale Of Assets				1.2		0
Equity compensation				(2.5)		(1.5)
Restructuring and other special items (2)	[2]			(2)		(4.5)
Noncontrolling interest				0.2		0.4
Other income (expense), net	[3]			(0.6)		(41.3)
Non-allocated corporate costs, net				(7.8)		(5.5)
Total unallocated costs	[1]			(13.9)		(52.4)
(Gain) / Loss on Contract Termination	[4]			0		29.8
Extinguishment of Debt, Gain (Loss), Net of Tax				0		(20.6)
Business Combination, Bargain Purchase, Gain Recognized, Amount Net of Tax		$ 7		0	[5]	7
Oral Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue				247.7		261.1
Segment EBITDA				51.1		57.7
Medication Delivery Solutions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue				55.7		56.9
Segment EBITDA				7.8		9.9
Development and Clinical Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue				122.9		103.1
Segment EBITDA				$ 27.2		$ 21.4
[1]	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
[2]	Segment results do not include restructuring and certain acquisition-related costs
[3]	Amounts primarily relate to foreign currency translation gains and losses during all periods presented. Prior period amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million, offset by an acquisition-related gain of $7.0 million.
[4]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.
[5]	During the three months ended September 30, 2014, the Company recorded a $7.0 million bargain purchase gain for an acquisition completed in July 2014.

Segment Information - Reconcili

Segment Information - Reconciliation of Earnings / (Loss) from Continuing Operations to Ebitda (Detail) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting [Abstract]
Extinguishment of Debt, Gain (Loss), Net of Tax	$ 0	$ (20.6)
Earnings/(loss) from continuing operations	8.9	(20.3)
Depreciation and amortization	35.5	35
Interest expense, net	22.7	35.5
Income tax (benefit)/expense	4.9	(14)
Noncontrolling interest	0.2	0.4
EBITDA from continuing operations	$ 72.2	$ 36.6

Segment Information - Total Ass

Segment Information - Total Assets for Each Segment and Reconciling in Consolidated Financial Statements (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 3,056.4	$ 3,145.4
Oral Technologies [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	2,426.3	2,477.3
Medication Delivery Solutions [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	242.7	247.8
Development and Clinical Services [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	688.5	703.2
Corporate and Eliminations [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ (301.1)	$ (282.9)

Supplemental Balance Sheet In63

Supplemental Balance Sheet Information - Inventory (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Inventory, Net [Abstract]
Raw materials and supplies	$ 89.6	$ 76.9
Work-in-process	28.2	26.3
Finished goods	46.5	43.8
Total inventories, gross	164.3	147
Inventory reserve	(13.4)	(14.1)
Inventories	$ 150.9	$ 132.9

Supplemental Balance Sheet In64

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expense, Current	$ 27.5	$ 22
Spare parts supplies	11.2	11.5
Deferred taxes	14.8	19.7
Other current assets	27.2	27.7
Prepaid expenses and other	$ 80.7	$ 80.9

Supplemental Balance Sheet In65

Supplemental Balance Sheet Information - Property and Equipment (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Property, Plant and Equipment, Net [Abstract]
Land Buildings And Improvements	$ 639	$ 637.6
Machinery, equipment, and capitalized software	728.8	727.9
Furniture and fixtures	10.6	10.1
Construction in progress	109.5	97.6
Property, plant, and equipment, at cost	1,487.9	1,473.2
Accumulated depreciation	(603.6)	(588)
Property, plant, and equipment, net	$ 884.3	$ 885.2

Supplemental Balance Sheet In66

Supplemental Balance Sheet Information - Other Assets Non Current (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Other Assets, Noncurrent [Abstract]
Deferred long term debt financing costs	$ 9.1	$ 9.5
Other Assets, Miscellaneous, Noncurrent	18.1	18.9
Other Assets, Noncurrent	$ 27.2	$ 28.4

Supplemental Balance Sheet In67

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Jun. 30, 2015
Balance Sheet Related Disclosures [Abstract]
Accrued employee-related expenses	$ 60.6	$ 87.8
Restructuring accrual	6.5	7.3
Deferred income tax	1.4	1.5
Accrued interest	0.3	0.2
Deferred revenue and fees	38	39
Accrued income tax	43.7	55.8
Other accrued liabilities and expenses	51	55.4
Other accrued liabilities	$ 201.5	$ 247

Subsequent Events Subsequent 68

Subsequent Events Subsequent Events (Details) $ in Millions	Oct. 29, 2015USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Repurchase Program, Authorized Amount	$ 100